Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 28

1.

Iranian national thalassaemia screening programme.

Samavat A, Modell B.

BMJ. 2004 Nov 13;329(7475):1134-7. No abstract available.

2.

A simplified screening strategy for thalassaemia and haemoglobin E in rural communities in south-east Asia.

Fucharoen G, Sanchaisuriya K, Sae-ung N, Dangwibul S, Fucharoen S.

Bull World Health Organ. 2004 May;82(5):364-72.

3.

Pharmacological treatment of monogenic disease.

Weatherall DJ.

Pharmacogenomics J. 2003;3(5):264-6. Review. No abstract available.

PMID:
14583796
4.

Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting.

Rahimy MC, Gangbo A, Ahouignan G, Adjou R, Deguenon C, Goussanou S, Alihonou E.

Blood. 2003 Aug 1;102(3):834-8. Epub 2003 Apr 17.

5.

Sickle cell anaemia: epidemiology and cost of illness.

Nietert PJ, Silverstein MD, Abboud MR.

Pharmacoeconomics. 2002;20(6):357-66. Review. Erratum in: Pharmacoeconomics 2002;20(12):853.

PMID:
12052095
6.

Inherited haemoglobin disorders: an increasing global health problem.

Weatherall DJ, Clegg JB.

Bull World Health Organ. 2001;79(8):704-12. Epub 2001 Oct 24.

7.

Prenatal diagnosis and screening of the haemoglobinopathies.

Cao A, Galanello R, Rosatelli MC.

Baillieres Clin Haematol. 1998 Mar;11(1):215-38. Review.

PMID:
10872479
8.

Sickle cell disease: clinical management.

Ballas SK.

Baillieres Clin Haematol. 1998 Mar;11(1):185-214. Review.

PMID:
10872478
9.

Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.

Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C.

Health Technol Assess. 2000;4(3):i-v, 1-99. Review. No abstract available.

10.

Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review.

Ashley-Koch A, Yang Q, Olney RS.

Am J Epidemiol. 2000 May 1;151(9):839-45. Review.

PMID:
10791557
11.

Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group.

de Silva S, Fisher CA, Premawardhena A, Lamabadusuriya SP, Peto TE, Perera G, Old JM, Clegg JB, Olivieri NF, Weatherall DJ.

Lancet. 2000 Mar 4;355(9206):786-91.

PMID:
10711926
12.

Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis.

Panepinto JA, Magid D, Rewers MJ, Lane PA.

J Pediatr. 2000 Feb;136(2):201-8.

PMID:
10657826
13.

Global epidemiology of hemoglobin disorders.

Angastiniotis M, Modell B.

Ann N Y Acad Sci. 1998 Jun 30;850:251-69.

PMID:
9668547
14.

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D.

N Engl J Med. 1998 Jul 2;339(1):5-11.

15.

Pathogenesis and treatment of sickle cell disease.

Bunn HF.

N Engl J Med. 1997 Sep 11;337(11):762-9. Review. No abstract available.

PMID:
9287233
16.

Treatment of beta-thalassemia.

Giardini C.

Curr Opin Hematol. 1997 Mar;4(2):79-87. Review.

PMID:
9107523
17.

Cost of hospitalizations associated with sickle cell disease in the United States.

Davis H, Moore RM Jr, Gergen PJ.

Public Health Rep. 1997 Jan-Feb;112(1):40-3.

18.

A scientific basis for cost-benefit analysis of genetics services.

Modell B, Kuliev AM.

Trends Genet. 1993 Feb;9(2):46-52.

PMID:
8456501
19.
20.

Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E.

Blood. 1995 Jul 15;86(2):776-83. Review.

Supplemental Content

Support Center